Rhinosinusitis cost-effectiveness of therapy

Jump to navigation Jump to search

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Dima Nimri, M.D. [2]

Overview

Cost-effectiveness of Therapy

Medical therapy vs. Surgery

Current literature suggests that in patients with refractory chronic rhinosinusitis endoscopic sinus surgery(ESS) is superior to continued medical therapy in terms of symptom relief, quality of life and cost effectiveness with reported incremental cost effectiveness ratio (ICER) of five to thirteen thousand dollars per quality adjusted life year (QALY). Medical therapy mostly helps maintain the quality of life and health-state utility of the patients.[1][2][3][4]

Biologic therapies

Biologic therapies are recently introduced alternative therapies for sever cases of chronic rhinosinusitis. However to date, there has been insufficient evidence in the literature regarding their health care, social and economic cost effectiveness. It is suggested that use of biologic agents could prevent recurrence of the disease, and subsequently decrease the direct and indirect costs of the surgery. On the other hand biologic therapies are expensive and require multiple visits to the health care provider.

References

  1. Patel ZM, Thamboo A, Rudmik L, Nayak JV, Smith TL, Hwang PH (2017). "Surgical therapy vs continued medical therapy for medically refractory chronic rhinosinusitis: a systematic review and meta-analysis". Int Forum Allergy Rhinol. 7 (2): 119–127. doi:10.1002/alr.21872. PMID 27863163.
  2. Codispoti CD, Mahdavinia M (2019). "A call for cost-effectiveness analysis for biologic therapies in chronic rhinosinusitis with nasal polyps". Ann Allergy Asthma Immunol. 123 (3): 232–239. doi:10.1016/j.anai.2019.07.004. PMID 31295554.
  3. Rudmik L, Soler ZM, Mace JC, Schlosser RJ, Smith TL (2015). "Economic evaluation of endoscopic sinus surgery versus continued medical therapy for refractory chronic rhinosinusitis". Laryngoscope. 125 (1): 25–32. doi:10.1002/lary.24916. PMC 4280303. PMID 25186499.
  4. Scangas GA, Su BM, Remenschneider AK, Shrime MG, Metson R (2016). "Cost utility analysis of endoscopic sinus surgery for chronic rhinosinusitis". Int Forum Allergy Rhinol. 6 (6): 582–9. doi:10.1002/alr.21697. PMID 26991813.

Template:WH Template:WS